Form 4: Century Therapeutics Grants Director 88,000 Stock Options

Century Therapeutics, Inc. granted Director Lee Han Myung 88,000 stock options with a $0.592 exercise price, vesting over 36 months.

Summary

• Century Therapeutics, Inc. (IPSC) issued 88,000 stock options to Director Lee Han Myung.
• The options have an exercise price of $0.592 per share.
• The grant was made on December 9, 2025, in connection with Lee Han Myung's appointment as a director.
• The options vest in equal monthly installments over 36 months, contingent on continued service to the company.
• The options were issued pursuant to the Company's 2021 Equity Incentive Plan and expire on December 9, 2035.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning management interests with shareholders. It does not contain any negative or unexpected information, indicating a stable and standard corporate action.

Positives

• The grant of stock options aligns the interests of Director Lee Han Myung with those of shareholders, incentivizing long-term company performance.
• The appointment of a new director, as indicated by this compensation, suggests ongoing board development and governance.

Risks

• The value of the stock options is subject to the future market price of Century Therapeutics, Inc. common stock, which can be volatile.
• The options' vesting is contingent on continued service, meaning the director must remain with the company for the full 36-month period to fully realize the grant.

Future Outlook

The vesting schedule over 36 months implies an expectation of continued service from Director Lee Han Myung, aligning his long-term commitment with the company's future performance.

Industry Context

The grant of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of equity compensation to attract and retain talent, and to align leadership interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a widely accepted practice across the biotech sector, comparable to compensation structures seen at companies like Moderna, BioNTech, or Regeneron, which frequently use equity to incentivize leadership.
• The vesting schedule of 36 months is typical for long-term incentive plans, similar to those observed in other growth-oriented companies where sustained performance and commitment are valued.

Management Changes

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Lee Han Myung constitutes a related party transaction, as it involves compensation to a member of the company's board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of director interests with long-term company performance through equity ownership.
• Employees: The use of an equity incentive plan for directors may signal a consistent approach to performance-based compensation across the organization.

Next Steps

• Director Lee Han Myung's continued service to Century Therapeutics, Inc. is required for the stock options to vest over the 36-month period.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a newly appointed director, which is a standard practice for aligning interests. It does not contain information that would fundamentally alter the investment thesis for Century Therapeutics, Inc., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Century Therapeutics, IPSC, Stock Options, Director Compensation, Equity Incentive Plan, Form 4, SEC Filing, Lee Han Myung, Corporate Governance